Exclusion/withdrawal after entry · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with placebo (moderate certainty).
1 finding from 1 review
Failure to maintain clinical or endoscopic remission · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
1 finding from 1 review
Failure to adhere to medication regimen · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse event · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with sulfasalazine (moderate certainty).
1 finding from 1 review
Breastfeeding · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Infant weight (where they were only receiving own mother's milk) at the end of the study (grams) ( · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Volume of breast milk at the latest time measured (mL) ( · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Adverse effects for the infant or mother · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Risk of HAE attacks (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in risk of HAE attacks (during compared with placebo (moderate certainty).
1 finding from 1 review
Change in number of HAE attacks (per week) · children or adults with Types I or II HAE
1 finding from 1 review
Mortality (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
1 finding from 1 review
Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE
1 finding from 1 review
Disability (any validated scale) (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
1 finding from 1 review
Non pelvic pain · women undergoing outpatient hysteroscopy
It is very uncertain whether oral NSAID changes non pelvic pain compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Allergic reaction · women undergoing outpatient hysteroscopy
It is very uncertain whether oral NSAID changes allergic reaction compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · women undergoing outpatient hysteroscopy
1 finding from 1 review
Pain score within 30 min of procedure · women undergoing outpatient hysteroscopy
1 finding from 1 review
Pain score more than 30 min after procedure · women undergoing outpatient hysteroscopy
1 finding from 1 review